This unrelated press release may help to explain:
RELEASE AT 6:30 AM EDST, WED. JUNE 11
Abbott Laboratories Licenses Arris Technology
South San Francisco, CA, June 11, 1997 -- Arris Pharmaceutical (Nasdaq: ARRS) today announced a new
collaboration with Abbott Laboratories of Abbott Park, IL. (NYSE:ABT) under the terms of which Arris will
transfer to Abbott specialized drug discovery technologies for application by Abbott in an undisclosed
proprietary research program. Financial terms of the agreement were not released, but the contract provides for
a license fee and royalties due upon commercialization of products resulting from the technology.
According to Dan Petree, Arris executive vice president for corporate development, "The transfer of certain
discovery technologies to Abbott reinforces the value of Arris' capabilities. These discovery technologies were
developed by Arris in order to be successful in other partnered research programs, but according to the terms
of those earlier agreements, Arris retained the rights to all novel core technologies. Under this contract, Abbott
will have rights to apply those particular discovery technologies to a specified, but undisclosed target, and Arris
has retained certain rights to transfer the technologies to other pharmaceutical companies in the future."
Arris Pharmaceutical uses an integrated drug discovery approach combining structure-based drug design,
combinatorial chemistry and its proprietary Delta Technology to discover and develop small molecule
therapeutics for existing markets where available therapies have significant limitations. Arris' research focus is
protease-based discovery programs targeting the inhibition of enzymes implicated in inflammatory and certain
other diseases such as asthma, blood clotting disorders, arthritis, osteoporosis, cancer and various infectious
diseases.
# # #
Contact: Dan Petree, E.V.P., Corporate Development, or Shari Annes, V.P., Investor Relations:
415/829-1000. Internet: arris.com.
|
